

Leading graphics

## Gap analysis: which diseases have treatments on the market or promise in the pipeline?

When pharmaceutical companies take action to improve access to medicine, it has the largest impact on their own products. The Access to Medicine Index has identified which products those are – as well as future products still in development – for 20 of the world's largest research-based pharmaceutical companies.

From these companies, the Index identified products on the market and R&D projects for 77 high-burden diseases, conditions and pathogens. This includes diseases with the largest global impact on health, such as malaria and tuberculosis, and ones that overwhelmingly affect people living in low- and middle-income countries, such as river blindness (trachoma) and skin conditions caused by sandfly bites.

### How many products and projects are there?

The Index identified 1,314 projects in development from the 20 companies. This includes everything sitting in preliminary and discovery stages of R&D, as well as potential products that are working their way through clinical trials. It also found 1,036 products for the diseases, conditions and pathogens in scope, mainly medicines and vaccines, as well as diagnostics.

#### **Pipeline: 1,314 projects in development**

945 R&D projects target lifestyle diseases

615 for cancer

42 for HIV/AIDS

31 for tuberculosis

4 for neonatal sepsis

#### **Portfolio: 1,036 products already available**

672 products target lifestyle diseases

201 for heart disease

109 for cancer

76 for HIV/AIDS

24 contraceptive methods

